Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9604 posts found.

ema_logo

EMA to cut activities as it forecasts loss of 30% of staff

August 2, 2018 Medical Communications, Research and Development EMA, London, UK, amsterdam, brexit, disruption, staff

The European Medicines Agency is set to enact temporary cuts in activities as it prepares for significant disruption in the …
News

Sanofi join AstraZeneca and MSD in stockpiling medicines, 1800 jobs at risk

August 1, 2018 Research and Development Jobs, Sanofi, brexit, manufacturing, stockpiling

French multinational Sanofi have begun stockpiling drugs in preparation for a no-deal Brexit. The company will join AstraZeneca and MSD …
News
otsuka_web

Otsuka scores EU schizophrenia approval, but acute myeloid leukaemia drug flops at Phase 3

August 1, 2018 Research and Development, Sales and Marketing Astex, Otsuka, Rxulti, guadecitabine, pharma, schizophrenia

It’s bittersweet news for Otsuka as it emerges that the European Commission saw fit to approve its therapy Rxulti (brexpiprazole) …
News

Pfizer notches two EU approvals, including Herceptin biosimilar

August 1, 2018 Research and Development, Sales and Marketing Cancer, EMA, EU, Genetech, Herceptin, Pfizer, Trazimera, Xeljanz, biosimilar, breast cancer, pharma

Pfizer is patting itself on the back after securing two new approvals in Europe within 24 hours: Xeljanz (tofacitinib citrate) …
News
ianread

Pharma CEO Ian Read forcasts rebate-free drug market

August 1, 2018 Research and Development CEO, Ian Read, PBMs, Pfizer, Rebates

The CEO of American multinational Pfizer has said that he believes the Trump administration will eliminate rebates on prescription drug …
News
john-milligan-thumbnail-300x300

Gilead’s CEO and Chairman to both step down before year’s end

July 30, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, pharma

Gilead has announced that its President and Chief Executive Officer Dr John Milligan (pictured) will be stepping down by the …
Appointment

Living with Behçet’s disease

July 30, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Behçet's disease, patient experience, pharma

Suzanne Morris speaks to Pharmafocus to discuss her life with Behçet’s disease, a rare condition characterised by the inflammation of …
Feature
shutterstock_38078521

Tonix plunges 68% after PTSD drug failure

July 30, 2018 Research and Development, Sales and Marketing PTSD, Tonmya, pharma, tonix

Tonix Pharmaceuticals has announced that it has terminated its Phase 3 study of Tonmya (cyclobenzaprine HCl sublingual tablets) in military-related …
News
sean-harper

Amgen announces resignation of two top executives

July 27, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Anthony C Cooper, R&D, biotech, retire, sean harper

Amgen’s head of R&D, Dr Sean Harper, has announced that he is retiring from his current position as Executive Vice …
Appointment
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

July 27, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, China, GSK, Gilead, J&J, JJ, Pfizer, Remicade, Roche, antimicrobial resistance, biosimilar, pharma, pricing, viagra

With the UK in the grip of a record-breaking heatwave, it’s hard to focus on much else over here, but …
News
takeda_usa_pharmaceuticals_u

Takeda’s Alunbrig topples Pfizer’s Xalkori in ALK-positive lung cancer

July 27, 2018 Medical Communications, Research and Development Alunbrig, Cancer, NSCLC, Pfizer, Takeda, Xalkori, lung cancer, pharma

Takeda has unveiled new Phase 3 data showing that its tyrosine kinase inhibitor (TKI) Alunbrig (brigatinib) not only met its …
News
gsk_boronia_australia

GSK forges $300m partnership with 23andMe to boost preclinical R&D

July 26, 2018 Research and Development 23andME, GSK, GlaxoSmithKline, collaboration, genetics, pharma

In a bid to supercharge its drug discovery efforts, GlaxoSmithKline has sealed a $300 million deal with personal genomics and …
News

Merck KGaA announces new Senior Vice President, Head of Global Affairs

July 26, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Dr Maria Rivas, Germany, Merck, Merck KGaA, research and development

Merck KGaA has announced the appointment of Dr Maria Rivas as Senior Vice President, Head of Global Affairs. Dr Rivas, …
Appointment

Gilead’s CEO and Chairman to both step down before year’s end

July 26, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, pharma

Gilead has announced that its President and Chief Executive Officer Dr John Milligan (pictured) will be stepping down by the …
News
394px-ad_versus_co

Eisai and Biogen’s Alzheimer’s drug slows progression in Phase 2 trials

July 26, 2018 Research and Development Alzheimer's disease, BAN2401, Biodgen, Eisai, phase 2, research

An experimental drug developed by the Massachusetts-based multinational Biogen and their Japanese partner Eisai has been shown to significantly slow …
News
The Gateway to Local Adoption Series

Latest content

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

March 18, 2026

AEON Biopharma appoints John Bencich as CFO

March 17, 2026

Canada awards CSL Seqirus with influenza pandemic vaccine contract

March 17, 2026

Helus Pharma appoints Jill Conwell as Chief People Officer

March 16, 2026

Coriolis Pharma opens new US headquarter and laboratory

March 16, 2026